SNX3-IN-1
Based on 1 Customer Validation
SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor. SNX3-IN-1 reduces SNX3 protein expression and inhibits SNX3-mediated activation of the Wnt/β-catenin signaling pathway. SNX3-IN-1 inhibits the proliferation and migration of pulmonary fibrosis-related cells, and decreases the expression of fibrosis markers α-SMA and COL-1. SNX3-IN-1 can be used in research related to pulmonary fibrosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.04%
- CAS No.: 2344793-72-0
- Formule: C23H24O6
- Masse moléculaire:396.43
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
SNX3-IN-1 (Compound LC4) inhibits the enhanced migratory capacity of fibroblasts overexpressing SNX3[1].
SNX3-IN-1 inhibits SNX3-induced β-catenin accumulation and nuclear localization in cells[1].
SNX3-IN-1 (10 μM) inhibits TGF-β1-induced α-SMA expression in AT2 cells and fibroblasts, thereby reducing fibrotic activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J Snx3-cTg mice (2 months old, male and female; spontaneous pulmonary fibrosis model); C57BL/6J N-Tg mice (2 months old, male and female; bleomycin-induced pulmonary fibrosis model)[1]
-
Dosage:10 mg/kg
-
Administration:intratracheal; once weekly; 3 weeks
-
Result:Mitigated Bleomycin (BLM) (HY-108345)-induced pulmonary functional injury, reduced fibrosis areas, lowered β-catenin protein levels, and decreased hydroxyproline concentration in N-Tg mice.
Reversed fibrotic effects associated with SNX3 overexpression in Snx3-cTg mice, including reducing lung injury, fibrosis areas, and β-catenin levels.
Demonstrated therapeutic efficacy equivalent to positive control pirfenidone in inhibiting BLM-induced pulmonary fibrosis.
Chemical Information
-
CAS No. 2344793-72-0
-
Appearance Solid
-
Masse moléculaire 396.43
-
Formule C23H24O6
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=C(OCC)C=C1O/2)C2=C\C3=CC(C)=C(OC(C)(C(O)=O)C)C(C)=C3
-
Sequence
Arg-His-Arg-Thr-Pro-Met-Phe-Tyr-Gly-Leu-Met-NH2
-
Sequence Shortening
RHRTPMFYGLM-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 50 mg/mL (126.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5225 mL | 12.6126 mL | 25.2251 mL | 63.0628 mL |
| 5 mM | 0.5045 mL | 2.5225 mL | 5.0450 mL | 12.6126 mL | |
| 10 mM | 0.2523 mL | 1.2613 mL | 2.5225 mL | 6.3063 mL | |
| 15 mM | 0.1682 mL | 0.8408 mL | 1.6817 mL | 4.2042 mL | |
| 20 mM | 0.1261 mL | 0.6306 mL | 1.2613 mL | 3.1531 mL | |
| 25 mM | 0.1009 mL | 0.5045 mL | 1.0090 mL | 2.5225 mL | |
| 30 mM | 0.0841 mL | 0.4204 mL | 0.8408 mL | 2.1021 mL | |
| 40 mM | 0.0631 mL | 0.3153 mL | 0.6306 mL | 1.5766 mL | |
| 50 mM | 0.0505 mL | 0.2523 mL | 0.5045 mL | 1.2613 mL | |
| 60 mM | 0.0420 mL | 0.2102 mL | 0.4204 mL | 1.0510 mL | |
| 80 mM | 0.0315 mL | 0.1577 mL | 0.3153 mL | 0.7883 mL | |
| 100 mM | 0.0252 mL | 0.1261 mL | 0.2523 mL | 0.6306 mL |
SNX3-IN-1 Related Classifications
HY-181439 Related Classifications
Powered by Bioz